NCT05896293View on ClinicalTrials.gov

Kisspeptin Administration Subcutaneously to Patients With IHH

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Hypogonadotropic Hypogonadism
Interventions
DRUG

kisspeptin 112-121

SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)

DRUG

leuprolide acetate

Single SC bolus

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Stephanie B. Seminara, MD

OTHER